Dr. Martens (LON:DOCS) Insider Giles Wilson Acquires 192 Shares of Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson purchased 192 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was purchased at an average price of GBX 78 per share, with a total value of £149.76.

Giles Wilson also recently made the following trade(s):

• On Thursday, December 11th, Giles Wilson acquired 197 shares of Dr. Martens stock. The shares were purchased at an average price of GBX 76 per share, for a total transaction of £149.72.
• On Tuesday, November 11th, Giles Wilson bought 176 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 85 per share, with a total value of £149.60.

Dr. Martens Price Performance

Shares of DOCS stock opened at GBX 75.95 on Friday. Dr. Martens plc has a twelve month low of GBX 43.02 and a twelve month high of GBX 100.87. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The stock has a fifty day simple moving average of GBX 77.89 and a two-hundred day simple moving average of GBX 83.45. The stock has a market capitalization of £734.10 million, a price-to-earnings ratio of 44.68, a P/E/G ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last announced its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DOCS has been the subject of several recent research reports. Berenberg Bank restated a “buy” rating on shares of Dr. Martens in a report on Thursday, November 27th. Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Dr. Martens presently has an average rating of “Moderate Buy” and a consensus price target of GBX 6,000.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.